SCHEMBL9880145

SCHEMBL9880145

CC(=O)C1C(C(=O)O)[C@H]2C=C[C@@H]1O2

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPM1B O75688 5/20 0.56
ALDH1A1 P00352 6/20 0.45
KMT2A Q03164 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16675540 1.00 PPM1B (0.56) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL819846 1.00 PPM1B (0.56) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL14516610 0.91 PPM1B (0.44) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL13480836 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL13897079 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL6778458 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL1005051 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL11393084 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL9697481 0.88 PPM1B (0.61) PPM1BALDH1A1KMT2AL3MBTL1KDM4E
SCHEMBL13002242 0.77 PPM1B (0.52) PPM1BALDH1A1KMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170259081-A1 METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE LIXTE BIOTECHNOLOGY, INC. (US) 2017-09-14 US disclosed
US-20170259081-A1 METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE LIXTE BIOTECHNOLOGY, INC. (US) 2017-09-14 US disclosed
US-9526915-B2 Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase LIXTE BIOTECHNOLOGY, INC. 2016-12-27 US disclosed
US-20130280210-A1 METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE LIXTE BIOTECHNOLOGY, INC. 2013-10-24 US disclosed
US-8329719-B2 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases LIXTE BIOTECHNOLOGY, INC. (US) 2012-12-11 US disclosed
US-20120135522-A1 METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 LIXTE BIOTECHNOLOGY, INC. 2012-05-31 US disclosed
US-20110287537-A1 NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES LIXTE BIOTECHNOLOGY, INC. 2011-11-24 US disclosed
US-8058268-B2 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases LIXTE BIOTECHNOLOGY, INC. (US) 2011-11-15 US disclosed
US-20100029683-A1 Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses LIXTE BIOTECHNOLOGY, INC. 2010-02-04 US disclosed
US-20100029484-A1 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2010-02-04 US disclosed
US-20100029640-A1 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases LIXTE BIOTECHNOLOGY, INC. 2010-02-04 US disclosed
US-20090035292-A1 Use of phosphatases to treat neuroblastomas and medulloblastomas LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029640-A1 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases SNCA, NLN, HTT PPM1B 2358/4885ALDH1A1 1929/4885KMT2A 3224/4885
US-20100029683-A1 Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses PSPH, PPP5C, BUB1B PPM1B 184/4885ALDH1A1 4732/4885KMT2A 3789/4885
US-20100029484-A1 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC PPM1B 3573/4885ALDH1A1 358/4885KMT2A 1912/4885
US-20130280210-A1 METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE PPP5C, BUB1B, CDC25C PPM1B 149/4885ALDH1A1 4528/4885KMT2A 3099/4885
US-20170259081-A1 METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE PPP5C, BUB1B, CDC25C PPM1B 149/4885ALDH1A1 4528/4885KMT2A 3099/4885
US-20090035292-A1 Use of phosphatases to treat neuroblastomas and medulloblastomas PPME1, PNKP, PPP6C PPM1B 15/4885ALDH1A1 811/4885KMT2A 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.